## Frederick S Robinson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7749678/publications.pdf

Version: 2024-02-01

12 papers 857 citations

758635 12 h-index 1125271 13 g-index

14 all docs

14 docs citations

14 times ranked 2084 citing authors

#	Article	lF	CITATIONS
1	Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Nature Medicine, 2018, 24, 1047-1057.	15.2	175
2	InÂVivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Cell Reports, 2016, 16, 133-147.	2.9	114
3	Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature, 2017, 542, 362-366.	13.7	105
4	High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer. Nature Communications, 2018, 9, 5079.	5.8	91
5	Somatic mutation distributions in cancer genomes vary with three-dimensional chromatin structure. Nature Genetics, 2020, 52, 1178-1188.	9.4	79
6	Pre-existing Functional Heterogeneity of Tumorigenic Compartment as the Origin of Chemoresistance in Pancreatic Tumors. Cell Reports, 2019, 26, 1518-1532.e9.	2.9	70
7	p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell, 2019, 35, 204-220.e9.	7.7	62
8	Mir-21–Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. Journal of Neuroscience, 2015, 35, 15097-15112.	1.7	53
9	A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis. Npj Breast Cancer, 2018, 4, 9.	2.3	32
10	Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. Gastroenterology, 2021, 161, 196-210.	0.6	23
11	Loss of ARID1A Promotes Epithelial–Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress. Cancer Research, 2021, 81, 332-343.	0.4	22
12	Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS–Dependent Pancreatic Ductal Adenocarcinoma. Cancer Research, 2019, 79, 5612-5625.	0.4	11